Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by Pandoraon Feb 24, 2021 5:37pm
120 Views
Post# 32653543

RE:news

RE:news
gunzod wrote: Ventripoint issues shares in final payment od Debenture interest.


A little different slant:

 

Ventripoint corrects share issuance from Feb. 10 PR

 

2021-02-24 16:14 ET - News Release

 

An anonymous director reports

CORRECTION -- VENTRIPOINT DIAGNOSTICS ISSUES SHARES IN FINAL PAYMENT OF DEBENTURE INTEREST

Ventripoint Diagnostics Ltd. has made a correction to its Feb. 10, 2021, press release. The Company has issued an aggregate of 96,961 shares, rather than the 131,430 shares previously announced, for the final interest payment of $23,274 on convertible debentures issued by the Company on February 6, 2020, replacement Convertible Debentures issued the same date, and Convertible Debentures issued September 11, 2020. The shares will be issued at a deemed price of $.24 per share. Two directors of the Company will receive a total of 30,186 common shares in final payment of $7,245.88 of interest on their debentures.

All convertible debentures have been converted and the Company is debt free.

<< Previous
Bullboard Posts
Next >>